Skip to main content
. Author manuscript; available in PMC: 2018 Jan 4.
Published in final edited form as: Eur Neuropsychopharmacol. 2014 Jun 13;24(9):1492–1499. doi: 10.1016/j.euroneuro.2014.06.002

Table 2.

Demographic and clinical description of the analyzed sample, comparing the ‘523’ S/S and VL/VL groups. No statistically-significant difference in any of the variables was found between the groups (S/S vs. VL/VL).

Variable All sample %/SD S/S %/SD VL/VL %/SD
Number 331 179 152
Males (N) 217 65.6% 118 65.92% 99 65.10%
Ashkenazi origin (N) 211 63.7% 118 65.92% 93 61.18%
APOE ε2 allele carriers (N) 47 14.2% 28 15.64% 19 12.50%
Age at cognitive evaluation 71.98 4.87 72.44 5.03 71.43 4.63
Years of education 13.36 3.18 13.16 3.15 13.60 3.21
Hemoglobin A1c (mean) 6.79 0.82 6.76 0.78 6.83 0.86
Creatinine (mean) 1.01 0.27 1.01 0.23 1.00 0.31
BMI (mean) 28.85 4.71 28.80 4.60 28.91 4.85
Total cholesterol (mean) 181.49 23.10 181.78 23.35 181.15 22.89
HDL (mean) 47.62 10.24 47.76 9.97 47.45 10.58
LDL (mean) 103.11 18.36 103.36 18.47 102.83 18.29
Triglyceride (mean) 155.36 56.25 155.59 54.77 155.09 58.13
Duration of disease (years) 10.62 0.85 10.61 0.74 10.64 0.98
Diastolic BP (mean) 85.02 16.10 83.54 15.37 86.76 16.79
Systolic BP (mean) 166.68 9.70 165.79 9.93 167.72 9.34